Long-term follow-up for patients from the EVEROLD study
Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation
University Hospital, Brest · NCT06504225
This study looks at how patients who had transplants are doing over the long term to see if there are any lasting effects or problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 260 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest (other) |
| Locations | 14 sites (Amiens and 13 other locations) |
| Trial ID | NCT06504225 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the long-term follow-up of patients who participated in the EVEROLD study, specifically those who have completed the M12 follow-up visit. The study aims to gather data on the outcomes and complications related to transplant procedures over an extended period. By monitoring these patients, researchers hope to gain insights into the long-term effects and potential failures associated with transplants. Participation is voluntary, and patients must consent to the use of their medical data for this purpose.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have previously participated in the EVEROLD study and completed the M12 follow-up visit.
Not a fit: Patients who oppose the use of their medical data or are under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the long-term outcomes of transplant patients, potentially improving future care and management strategies.
How similar studies have performed: While this study is observational and focuses on long-term follow-up, similar studies have shown success in understanding transplant outcomes, making this approach valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed patients participating to the EVEROLD study * Patient having completed the EVEROLD M12 follow-up visit * Patient agreeing to participate in the observational study Exclusion Criteria: * Opposition to the use his medical data * Patient under legal protection
Where this trial is running
Amiens and 13 other locations
- Chu Amiens — Amiens, France (RECRUITING)
- CHU Bordeaux — Bordeaux, France (RECRUITING)
- Chu Brest — Brest, France (RECRUITING)
- CHU Lille — Lille, France (RECRUITING)
- CHU Limoges — Limoges, France (RECRUITING)
- CHU Nice Pasteur 2 — Nice, France (RECRUITING)
- CHU Nice — Nice, France (RECRUITING)
- Hôpital Necker — Paris, France (RECRUITING)
- Chu Poitiers — Poitiers, France (RECRUITING)
- CHU Rennes — Rennes, France (RECRUITING)
- CHU Rouen — Rouen, France (RECRUITING)
- CHU Strasbourg — Strasbourg, France (RECRUITING)
- CHU Toulouse Rangueil — Toulouse, France (RECRUITING)
- CHU Tours — Tours, France (RECRUITING)
Study contacts
- Principal investigator: Yannick LE MEUR — CHU Brest
- Study coordinator: Yannick Le Meur
- Email: yannick.lemeur@chu-brest.fr
- Phone: +330298347014
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Transplant, Complication, Failure